ArticleAnnals of medicine and surgery (2012)2025
AI-based histopathology and radiomics fusion for predicting surgical margins in colorectal cancer: improving oncological outcomes through multimodal AI integration.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving negative surgical margins is fundamental to curative colorectal cancer (CRC) surgery. Despite advancements in imaging, preoperative identification of margin risk remains limited. Recent developments in artificial intelligence (AI) now enable fusion of radiomics, quantitative imaging analysis, and histopathology ("pathomics") to predict microscopic tumor spread more accurately. Radiomics captures sub-visual textural and spatial features from CT and MRI, while AI-driven histopathology interprets digital slides at cellular resolution. Integrating these modalities yields a multi-scale model that reflects both macroscopic tumor architecture and microscopic invasiveness. Multicentric studies in China and the US have demonstrated superior performance of radiopathomic models over single-modality approaches for predicting therapeutic response and margin status. As countries such as the United Kingdom and South Korea implement AI-driven precision oncology frameworks, transparent validation remains essential. By enabling more informed surgical planning and tailored resections, multimodal AI fusion could markedly enhance oncological outcomes in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.